Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum StockZacks Investment Research • 12/22/25
Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026Business Wire • 12/18/25
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett SyndromeBusiness Wire • 12/12/25
Buy Acadia Pharmaceuticals For Daybue/Nuplazid Stability And Pipeline OptionalitySeeking Alpha • 12/04/25
Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound?The Motley Fool • 12/04/25
ACADIA Pharmaceuticals Inc. (ACAD) Presents at Citi Annual Global Healthcare Conference 2025 TranscriptSeeking Alpha • 12/02/25
Acadia Pharmaceuticals to Participate in Citi's 2025 Global Healthcare ConferenceBusiness Wire • 11/20/25
Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-TermZacks Investment Research • 11/12/25
ACADIA Pharmaceuticals Inc. (ACAD) Presents at UBS Global Healthcare Conference 2025 TranscriptSeeking Alpha • 11/10/25
ACAD Q3 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue GrowthZacks Investment Research • 11/06/25
Acadia Pharmaceuticals (ACAD) Q3 Earnings and Revenues Top EstimatesZacks Investment Research • 11/05/25
Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating OverviewBusiness Wire • 11/05/25
Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 10/29/25
Does Acadia (ACAD) Have the Potential to Rally 27.66% as Wall Street Analysts Expect?Zacks Investment Research • 10/28/25
Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their RightsBusiness Wire • 10/22/25
Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025Business Wire • 10/15/25
Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson's Disease and Movement Disorders®Business Wire • 10/02/25
ACAD Stock Down 10% Following Phase III Hyperphagia Study FailureZacks Investment Research • 09/25/25
Acadia Pharma Tumbles On Failed Appetite Suppressant; Soleno SurgesInvestors Business Daily • 09/24/25